With the rapid development in science and technology,more and more advanced medical devices have been used in clinical practice.Consequently,the maintenance and management of the devices has become a task of modern hospitals.In this paper,the author discusses some issues for their maintenance and management.

OBJECTIVE:To observe long-term efficacy of intensive rosuvastatin therapy in the treatment of acute coronary syn-drome (ACS) and explore its possible mechanism,so as to provide reference for clinical diagnosis and treatment. METHODS:ACS patients receiving rosuvastatin after cured in our hospital during Jan. 2013-Jan. 2015 were divided into observation group(55 cases)and control group(47 cases)according to the dose of rosuvastatin. Under same guidance of physicans,2 groups were addi-tionally given Rosuvastatin calcium tablets(20 mg for observation group,10 mg for control group,qd,po)orally on the basis of routine treatment. Both groups were treated for 1 year. The incidence of 1-year accumulative main adverse cardiac event (MACE) were compared between 2 groups as well as the levels of blood lipid and serum cytokines,the occurrence of ADR before treat-ment,after 3 months of treatment. RESULTS:The incidence of accumulative MACE in observation group was significantly lower than control group,with statistical significance (P<0.05). After treatment,the levels of TC and LDL-C in 2 groups were de-creased significantly;the level of LDL-C was inCreased significantly compared to before treatment,and the observation group was significantly lower than the control group,with statistical significance(P<0.05). The levels of IL-1β and TNF-α in 2 groups were decreased significantly (P<0.05);the observation group was significantly lower than the control group,with statistical signifi-cance (P<0.05). The peripheral blood LDL-C was positively correlated with IL-1β and TNF-α in observation group after treat-ment,with statistical significance(P<0.05). There was no statistical significance in the incidence of ADR between 2 groups(P>0.05). CONCLUSIONS:Intensive rosuvastatin therapy can significantly improve the long-term prognosis for ACS patients,which may associate with lipid metabolic regulation and anti-inflammatory effect.

Objectives To evaluate the effectiveness and safety of peramivir trihydrate in patients with influenza.Methods This was a randomized,double-blind,double-dummy,placebo and positive control,multicenter clinical trial,comparing peramivir trihydrate with oseltamivir and placebo.The inclusive criteria were 15-70 years old,onset within 48 h,positive rapid influenza antigen test,and febrile(＞38℃) accompanied with at least two associated symptoms.The severe cases complicated with chronic pulmonary and cardiac diseases,malignancies,organ transplantation,hemodialysis,uncontrolled diabetes,immunocompromised status,pregnancy and coexistence of bacterium infections were excluded.All patients were randomized 2:2:1 to receive peramivir,oseltamivir and placebo respectively.The primary endpoint was the disease duration,the secondary endpoints included time to normal axillary temperature and normal living activities,viral response,and adverse effects.Results Following informed consent,133 patients were included in this study.Four patients were exclude due to missing medical records,not fitting inclusion or exclusion criteria and poor compliance.A total of 129 patients were finally analyzed,including 49 cases,54 cases and 26 cases in peramivir group,oseltamivir group and placebo group.The median disease duration were 96 (76,120)hours,105(90,124) hours,and 124 (104,172)hours in three groups respectively(P＞0.05).The time to normal axillary temperature,normal living activities and viral response were not significantly different in three groups(P＞0.05).Conclusion The value of antiviral therapy in patients with mild influenza needs to be further determined.